Dec 08, 2021 10:22 PM (GMT+8) · EqualOcean
In December 8th, the State Administration of pharmaceuticals for emergency approval of Tengsheng Huachang Pharmaceutical Technology (Beijing) Co., Ltd. COVID-19 neutralization antibody combination treatment of BRII-196 and BRII-198. It is reported that this is the first self-designed intellectual property COVID-19 neutralizing antibody combination drug in China. According to the relevant provisions of the drug administration law, the State Food and drug administration shall carry out emergency review and approval according to the special approval procedures of drugs, and approve the combination of the above two drugs for the treatment of light and ordinary adults and adolescents (12 to 17 years old, weighing more than 40kg) with New Coronavirus infection (COVID-19) who are highly risk factors (including hospitalization or death). Among them, adolescents (12-17 years old, weight ≥ 40kg) with indications are subject to conditional approval.

This text is a result of machine translation.